Figure 2From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesDurations of response for patients who achieved CR/CRu on romidepsin (investigator assessed; n = 21). Only investigators assessed DOR for prior therapy (for patients with PR or CR on prior therapy). Arrows indicate that the patient was censored while in response. * Indicates that the patient received combination chemotherapy as the last prior therapy. NR indicates that the response to prior therapy was not reported.Back to article page